Obseva (NASDAQ:OBSV) Raised to “Hold” at Zacks Investment Research

Obseva (NASDAQ:OBSV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Zacks.com reports.

According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “

OBSV has been the subject of several other reports. Wedbush restated a “buy” rating and issued a $38.00 price objective on shares of Obseva in a report on Thursday, October 31st. ValuEngine upgraded Obseva from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Credit Suisse Group downgraded Obseva from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $16.00 to $4.00 in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $44.00 price objective on shares of Obseva in a report on Wednesday, September 4th. Finally, BidaskClub upgraded Obseva from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $24.75.

Shares of OBSV opened at $2.76 on Friday. The firm has a market capitalization of $136.43 million, a P/E ratio of -1.45 and a beta of 0.82. Obseva has a 12-month low of $2.70 and a 12-month high of $16.49. The company has a current ratio of 3.65, a quick ratio of 3.67 and a debt-to-equity ratio of 0.38. The firm has a fifty day moving average price of $7.38 and a 200-day moving average price of $9.98.

Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.19. Analysts predict that Obseva will post -3.03 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in OBSV. Wedbush Securities Inc. raised its holdings in Obseva by 54.2% in the third quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock worth $334,000 after purchasing an additional 14,100 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Obseva by 263.6% during the second quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after acquiring an additional 2,372 shares during the last quarter. Morgan Stanley grew its stake in shares of Obseva by 358.6% during the second quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after acquiring an additional 2,424 shares during the last quarter. AXA grew its stake in shares of Obseva by 7.8% during the second quarter. AXA now owns 500,313 shares of the company’s stock worth $5,659,000 after acquiring an additional 36,356 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Obseva by 7.6% during the second quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock worth $900,000 after acquiring an additional 5,600 shares during the last quarter. Institutional investors and hedge funds own 64.00% of the company’s stock.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: What is the balance sheet?

Get a free copy of the Zacks research report on Obseva (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.